Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Anti-Cancer Drugs
|
September 15, 2017
Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer
Mamoru Ito, Hitoshi Kusaba, Satomi Mukaide, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
August 12, 2017
Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
Akitaka Makiyama, Kohei Arimizu, Gen Hirano, et al.
Clinical Colorectal Cancer
|
September 18, 2022
WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF<sup>V600E</sup> Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study)
Keitaro Shimozaki, Kenro Hirata, Taro Sato, et al.
Molecular and Clinical Oncology
|
May 19, 2017
Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans
Kenji Tsuchihashi, Hitoshi Kusaba, Yuichi Yamada, et al.
JCO Precision Oncology
|
August 11, 2022
Association of <i>ERBB2</i> Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric Cancer
Kaori Hino, Tomohiro Nishina, Takeshi Kajiwara, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
December 31, 2024
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS
Azusa Komori, Shuichi Hironaka, Shigenori Kadowaki, et al.
International Journal of Clinical Oncology
|
March 4, 2026
Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
Ryosuke Kawagoe, Toshikazu Moriwaki, Kentaro Yamazaki, et al.
Frontiers in Oncology
|
July 2, 2021
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
Hiromichi Nakajima, Shota Fukuoka, Toshiki Masuishi, et al.
Frontiers in Oncology
|
March 25, 2021
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
Keigo Chida, Daisuke Kotani, Toshikazu Moriwaki, et al.
International Journal of Cancer
|
July 23, 2025
Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G)
Yuki Matsubara, Toshiki Masuishi, Waki Hosoda, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Anti-Cancer Drugs
|
September 15, 2017
Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer
Mamoru Ito, Hitoshi Kusaba, Satomi Mukaide, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
August 12, 2017
Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
Akitaka Makiyama, Kohei Arimizu, Gen Hirano, et al.
Clinical Colorectal Cancer
|
September 18, 2022
WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF<sup>V600E</sup> Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study)
Keitaro Shimozaki, Kenro Hirata, Taro Sato, et al.
Molecular and Clinical Oncology
|
May 19, 2017
Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans
Kenji Tsuchihashi, Hitoshi Kusaba, Yuichi Yamada, et al.
JCO Precision Oncology
|
August 11, 2022
Association of <i>ERBB2</i> Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric Cancer
Kaori Hino, Tomohiro Nishina, Takeshi Kajiwara, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
December 31, 2024
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS
Azusa Komori, Shuichi Hironaka, Shigenori Kadowaki, et al.
International Journal of Clinical Oncology
|
March 4, 2026
Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
Ryosuke Kawagoe, Toshikazu Moriwaki, Kentaro Yamazaki, et al.
Frontiers in Oncology
|
July 2, 2021
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
Hiromichi Nakajima, Shota Fukuoka, Toshiki Masuishi, et al.
Frontiers in Oncology
|
March 25, 2021
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
Keigo Chida, Daisuke Kotani, Toshikazu Moriwaki, et al.
International Journal of Cancer
|
July 23, 2025
Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G)
Yuki Matsubara, Toshiki Masuishi, Waki Hosoda, et al.
Page
of 4